Skip to main content
. Author manuscript; available in PMC: 2011 Nov 16.
Published in final edited form as: Cancer Cell. 2010 Nov 16;18(5):423–435. doi: 10.1016/j.ccr.2010.10.025

Figure 1. Coexpression of HER2 and EpoR in Human Breast Cancer Cell Lines.

Figure 1

(A) Expression of HER2 and EpoR in human breast cancer cell lines. Exponentially proliferating breast cancer cells of the indicated lines were harvested by trypsinization. Equal amounts of cell lysates were subjected to Western blot analysis with specific antibodies directed against EpoR and HER2. The level of β-actin served as a protein-loading control.

(B) Expression knockdown of EpoR by RNAi. MCF7 cells were subjected to EpoR expression knockdown with EpoR-specific Dharmacon SMARTpool siRNA or control siRNA for the indicated durations. Cell lysates were prepared, and the levels of EpoR were measured by Western blot analysis with EpoR-specific antibody. The level of β-actin served as a protein-loading control.

(C) Coexpression of HER2 and EpoR. MDA453 and MCF7-HER18 cells were subjected to double-immunofluorescent staining with primary antibodies directed against EpoR (rabbit IgG) and HER2 (mouse IgG), followed by incubation with FITC-labeled goat anti-mouse IgG antibody and Cy3-labeled goat anti-rabbit IgG antibody. The cell suspensions were then analyzed by flow cytometry. See also Figure S1.